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1. Introduction
Posterior ischemic optic neuropathy is a disorder of 
reduced blood flow to the retrobulbar optic nerve, 
usually of acute onset. This condition can be classified 
as surgical, arteritic or non-arteritic (1,2). Use of high-
dose systemic steroids to treat non-arteritic posterior 
ischemic optic neuropathy (NA-PION) results in 
improved visual acuity (2). Steroid therapy is not 
universally successful. 
 Prostaglandin E1 (PGE1), a powerful vasodilator of 
the microcirculation, improves ocular blood flow in the 
presence of peripheral vascular disease and diabetes (3). 
In cases of NA-PION, PGE1 was given intravenously 
at a dose of 1 μg/kg with steroids and was found to 
improve visual acuity as well as ocular and retrobulbar 
blood flow (4,5). In the current case, visual fields as 
well as visual acuity were improved in a patient with 
NA-PION treated with intravenous PGE1 and steroids 
66 hours after onset.
2. Case Report
An 89-year-old white female was seen in December 
2016. She had dry age-related macular degeneration 
in the right eye and a neovascular membrane in the 
left eye. One morning three days prior, she underwent 
ocular surgery with the Limoli retinal restoration 
technique on her right eye. This technique involves 
placing a cellular autograft in an equatorial scleral 
pocket of the eye (6). Eight hours after surgery while 
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watching television in the evening, she had a sudden 
decrease in the visual acuity in the right eye (the eye 
that underwent surgery). She was examined 63 hours 
later. She was pseudophakic in both eyes with a visual 
acuity of 1/10 + 1 in the right eye according to the 
Early Treatment Diabetic Retinopathy Study chart and 
a visual acuity of 1/30 in the left eye. The intraocular 
pressures were normal with no signs of secondary 
cataracts. There were no clinical signs of giant cell 
arteritis. Her blood work from surgery did not indicate 
signs of diabetes or giant cell arteritis. A fundus 
exam revealed dry age-related macular degeneration 
in the right eye with no signs of retinal hemorrhage, 
inflammation or edema. Edema was present in the 
fundus of the left eye. The optic nerve heads were 
normal in both eyes with no pallor or edema. Optical 
coherence tomography revealed no signs of fluid in 
the macula in the right eye and an optical coherence 
tomography angiography revealed no signs of a 
neovascular membrane in the right eye. A neovascular 
membrane was present in the left eye. Humphrey 
central 24-2 visual field testing was immediately done. 
In the right eye, there was a mean deviation of – 7.10 
decibels (dB) with a central scotoma of – 22 dB (Figure 
1 and Table 1). The visual field in the left eye could not 
be tested due to lack of central fixation. 
 The patient was diagnosed with NA-PION. The 
experimental nature of the treatment was explained 
and after written consent was obtained, treatment was 
immediately begun 66 hours after onset. PGE1 comes 
as a liquid in vials of 20 μg and is given intravenously 
in physiologic solution at a dose of 1 μg/kg. The patient 
weighed 68 kilograms and was started on 60 μg of PGE1 
administered intravenously over 1 hour. Subjectively, 
she noted a gradual return in the visual acuity in the right 
eye the same evening after treatment. The following 
morning, PGE1 was administered again intravenously 
and the patient was started on 25 mg of prednisone once 
a day for 5 days. Five days after the first treatment, she 
was examined. Visual acuity in the right eye was 7/10 + 3. 
There was no change in the left eye. Other results of the 
exam, including the fundus, remained the same. Visual 
field testing of the right eye revealed a mean deviation 
of – 2.97 dB with a central scotoma of – 19 dB (Figure 1 
and Table 1). Two weeks later, visual acuity was 7/10 + 
1 and visual field testing of the right eye revealed a mean 
deviation of – 2.54 dB with a central scotoma of – 9 dB 
(Figure 2 and Table 1). The patient was continued on 
60 μg of PGE1 in the form of a skin cream for systemic 
absorption every 2 weeks. One, 4 and 7 months (at 
the time of this report), her vision was stable and she 
continued to use PGE1 skin cream every 2 weeks.
3. Discussion
The purpose of this case report is to present further 
evidence, which includes improvement in visual fields, 
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Figure 1. Visual field of the right eye on the left side before treatment and the visual field of the right eye on the right side 
5 days post-treatment.
Table 1. Visual acuity and Humphrey 24.2 visual fields of 
the right eye before and after treatment with prostaglandin 
E1 (PGE1) 
Date
Initial visit (T0)
After 5 days (T5)
After 2 weeks (T2ws)
  Visual
 Acuity
1/10 + 1
7/10 + 3
7/10 + 1
   Mean
Deviation
– 7.10 dB
– 2.97 dB
– 2.54 dB
dB: decibels.
 Central
Scotoma
– 22 dB
– 19 dB
–   9 dB
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during its intravenous administration (3,7). The main 
mechanism of action of PGE1 is via vasodilatation 
of the microcirculation. PGE1 has a direct action 
on the smooth muscle of the vascular wall, leading 
to a vascular dilatation and increased flow. PGE1 
is rapidly metabolized by oxidation during passage 
through the pulmonary circulation. It is excreted in the 
urine as metabolites within about 24 hours. This rapid 
elimination also contributes to its safety (10). 
 The current patient had poor vision in the left eye 
because of a neovascular membrane. Ischemic episodes 
in NA-AION and NA-PION are known to reoccur in 
the affected eye or in the other eye (5,11). To avoid 
another episode in the good eye, the authors wanted to 
maintain vasodilatation of the microcirculation with 
PGE1 without resorting to intravenous treatments. 
Accordingly, the patient continued to receive 60 μg of 
PGE1 in a skin cream. The PGE1 concentration in this 
cream is 20 μg/cc. Three cc of cream, for a total dosage 
of 60 μg of PGE1, is applied in repeated individual 
doses over 2 hours to the inner surface of the forearm, 
spread and allowed to dry. This allows for systemic 
absorption over 2 hours. This is done every 2 weeks. 
This is a compound pharmacy preparation that has been 
patented by one of the authors (RDS). 
 Steroids, in the form of prednisone, were given 
orally to the current patient for 5 days. Systemic steroids 
have been used to treat NA-PION and NA-AION 
(2,12). Steroid therapy is, however, not universally 
accepted. A more recent study using high-dose systemic 
steroid treatment in acute NA-AION noted no visual or 
anatomic benefit and some serious complications due to 
steroids (13). However, the current authors used steroids 
for another reason: to try to reduce ischemia-reperfusion 
injury. Ischemia leads to tissue hypoxia, depletion of 
energy-rich phosphates, accumulation of metabolic waste 
products including reactive oxygen species and cellular 
edema, all of which may cause cellular injury (14,15). 
The immediate resumption of blood flow is necessary 
to prevent further tissue damage but the reperfusion 
itself may cause further tissue damage via reperfusion 
injury. Infiltrating leukocytes are thought to play a major 
role in this ischemia-reperfusion injury (14,15), and 
this was why the current authors administered 25 mg of 
prednisone along with PGE1 during the first 5 days. 
 Surgery with the Limoli retinal restoration technique 
was done 8 hours prior to the loss of vision. This 
technique involves fashioning a scleral pocket at the 
equator of the eye filled with adipose stromal cells 
derived from orbital fat, platelets from platelet-rich 
plasma and adipose-derived stem cells from abdominal 
adipose tissue. This is meant to bring nutrition to the 
choroid and retina (6). Upon examination of the patient 
after the visual loss, there were no signs of unusual 
ocular or orbital inflammation due to the surgery. The 
authors do not think that the surgery was the cause of 
NA-PION. 
for the use of intravenous PGE1 and steroids in the 
treatment of NA-PION. The authors also intend to 
describe how that treatment, even though it was delayed 
up to 66 hours after onset, was still beneficial. 
 NA-PION is a disorder of reduced blood flow 
to the retrobulbar optic nerve (1,2,5). The use of a 
potent vasodilator, PGE1, to immediately re-establish 
blood flow could be important (3,7). PGE1 given 
intravenously at a dose of 1 μg/kg together with 
steroids has been successfully used to treat cases of 
NA-PION and acute non-arteritic anterior ischemic 
optic neuropathy (NA-AION) (4,5,8). PGE1 has helped 
in the treatment of acute arteritic anterior ischemic 
optic neuropathy when given with high-dose steroids 
(9). In the current case, intravenous PGE1 and steroids 
were immediately started as soon as the patient was 
diagnosed with NA-PION, resulting in an improvement 
in visual fields and visual acuity. This is the first report 
of improvement in visual fields in NA-PION and is 
further evidence for this therapy. Based on the authors’ 
clinical experience with cases of NA-AION, PGE1 
must be given immediately, i.e. within 12 hours, to 
be effective. In the current case involving NA-PION, 
the therapy was effective even after 66 hours, so this 
therapy should be attempted. One intravenous infusion 
of PGE1 improves peripheral blood flow for up to 4 
weeks in patients with peripheral vascular disease (3,7). 
Because of this, PGE1 was given only 2 times over 
2 days and was effective. Repeated treatments could 
lead to systemic hypotension. The dosage is 1 μg/kg 
in physiologic solution over 1 hour. Higher dosages 
could also lead to systemic hypotension. PGE1 is well-
tolerated and causes few adverse reactions, so it can 
be used in patients who are hypotensive. Systemic 
blood pressure needs to be monitored frequently 
Figure 2. Visual field of the right eye 2 weeks post-
treatment.
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 In the current case, visual field testing was possible 
before treatment without an unusual delay in treatment, 
so this testing was done immediately. The Humphrey 
visual field improved after treatment, with a reduction 
in the mean deviation from – 7.10 to – 2.54 dB. The 
central scotoma improved from – 22 to – 9 dB (Table 1 
and Figures 1 and 2). This paralleled the improvement 
in the visual acuity from 1/10- to 7/10 + 1, which is 
consistent with her age-related macular degeneration. 
In another case of NA-PION, vision improved to 11/10 
with no central scotoma on visual fields tested only after 
treatment (5). In that case, treatment was administered 
within 24 hours and there was no age-related macular 
degeneration. In the current case, improvement in visual 
fields and the central scotoma are evidence of the benefit 
of therapy even though it started 66 hours after onset. 
 This case report describes the beneficial use of 
intravenous PGE1 and steroids in the treatment of NA-
PION even though that treatment started 66 hours after 
onset. The addition of steroids may help to reduce 
damage from ischemia-reperfusion injury, but this point 
needs to be evaluated further. In order to provide the 
complete clinical picture, use of PGE1 was continued 
in the form of a skin cream every 2 weeks to avoid 
recurrence; however, this approach also needs to be 
properly studied. 
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